| إسرائيل | تركيا | إسبانيا | |
| العلاج الكيميائي لسرطان الثدي | من $22,500 | من $1,200 | من $3,500 |
| العلاج الإشعاعي لسرطان القولون والمستقيم | - | من $7,000 | من $10,000 |
تتخصص الدكتورة بيليس شارون في علاجات سرطان الكبد المتقدمة في مركز سوراسكي الطبي، بما في ذلك استئصال الكبد والانصمام الكيميائي.
يقود البروفيسور ميريمسكي وحدة أورام الأنسجة الرخوة والعظام في مركز سوراسكي الطبي، وهو متخصص في حالات السرطان المعقدة.
يرأس البروفيسور نادير أربر مركز الوقاية المتكاملة من السرطان في مركز سوراسكي الطبي في إسرائيل، وهو متخصص في أورام الجهاز الهضمي.
الدكتور أرنون ناغلر أخصائي أمراض الدم وخبير زراعة نخاع العظم معترف به دوليًا. وهو أستاذ طب في جامعة تل أبيب. يشغل منصب المدير الفخري لأمراض الدم وزراعة نخاع العظم وبنك دم الحبل السري في مركز شيبا الطبي. حصل على درجة دكتوراه في الطب من الجامعة العبرية–هداسا، وعلى ماجستير في تكوّن الدم من جامعة تل أبيب. أنهى تدريب ما بعد الدكتوراه في ستانفورد، ويحمل شهادة البورد في الطب الباطني وأمراض الدم.
لديه أكثر من 35 عامًا من الخبرة. كان رائدًا في بروتوكولات الزراعة الخيفية منخفضة الشدة للأمراض الخبيثة وغير الخبيثة. أسس أول بنك عام لدم الحبل السري في إسرائيل، وأجرى أولى عمليات زراعة دم الحبل السري في البلاد.
شغل مناصب قيادية دولية. تولى رئاسة ومشاركة رئاسة ALWP التابعة لـ EBMT، وكان نائبًا للرئيس وعضوًا طويل الأمد في لجان EBMT. وكان عضوًا في مجلس إدارة NetCord/EuroCord وتولى منصب أمين الصندوق. وهو متحدث مدعو بانتظام، ونشر على نطاق واسع في مجلات مثل Blood وLeukemia. قاد تجارب سريرية كبرى بصفته الباحث الرئيسي وتولى أدوارًا تحريرية. ونال جوائز عديدة عن الابتكار والتميّز السريري.
Stage 3 liver cancer is treatable with surgery in Israel if the tumor is resectable and liver function remains stable. Specialists use advanced procedures like partial hepatectomy or ex-vivo resection. Eligibility depends on vascular involvement and the absence of distant metastasis.
Bookimed Expert Insight: Data shows that choosing high-volume centers like Sheba or Sourasky is vital for complex stages. These facilities perform over 34,000 to 45,000 operations annually. This high frequency allows surgeons to maintain expertise in rare procedures like ex-vivo resection. Patients benefit from multidisciplinary teams that often re-evaluate cases initially labeled as inoperable elsewhere.
Patient Consensus: Patients note that a second opinion is essential because assessments of operability vary between surgeons. They emphasize asking exactly why surgery is not recommended to explore downstaging options.
Israeli hospitals provide advanced non-surgical local therapies including transarterial chemoembolization (TACE), selective internal radiation therapy (SIRT), and microwave ablation. These minimally invasive procedures target stage 3 tumors when surgery is not possible. Specialized JCI-accredited centers use these techniques to halt progression.
Bookimed Expert Insight: Data shows Israeli specialists like Dr. Pelles Sharon at Sourasky Medical Center often combine SIRT with immunotherapy. This dual approach is common in high-volume clinics like Sheba, which treats over 1,900,000 patients annually. While ablation is standard for small nodules, Israeli oncologists frequently use microwave ablation for larger stage 3 masses. This is possible due to the high density of robotic and digital imaging technologies at these academic centers.
Patient Consensus: Patients note that TACE is a common bridge therapy to slow tumor growth. Many emphasize that doctors prioritize liver function scores over tumor stage when choosing between radiation and embolization.
Advanced and experimental therapies are widely available in Israel for inoperable cancer. Patients access cutting-edge protocols through international clinical trials and compassionate use programs. Leading academic centers specialize in cellular immunotherapies, precise radioactive micro-technologies, and molecularly targeted biological regimens for unresectable tumors.
Bookimed Expert Insight: Israeli oncology centers like Sheba Medical Center and Sourasky (Ichilov) often successfully downstage tumors once labeled inoperable. Prof. Dr. Almog Ben Yaacov at Sheba, for instance, uses microwave liver ablation and robot-assisted technology to treat complex cases. A high volume of clinical trials and 90% oncology success rates at Ichilov indicate that multidisciplinary reviews frequently find new surgical or systemic pathways.
Patient Consensus: Patients emphasize the value of a multidisciplinary tumor board review. Inoperable status can change after evaluation by a hepatobiliary surgeon and an interventional radiologist together.
Israeli medical centers like Sheba and Sourasky lead in treating Stage 3 liver cancer through multidisciplinary tumor boards. These JCI-accredited facilities provide advanced therapies including SIRT radioembolization and complex hepatectomy. High survival rates are achieved using integrated surgical oncology and personalized immunotherapy protocols.
Bookimed Expert Insight: Israeli oncology centers demonstrate high expertise through specialized leadership roles. Dr. Yuri Goldes at Sheba pioneered the first robotic oncologic resections in Israel. This technical depth allows for minimally invasive approaches even in complex Stage 3 cases. Patients benefit from surgeons who perform over 200 specialized procedures like HIPEC annually.
Patient Consensus: Patients emphasize that top-tier results come from hospitals using full liver tumor boards. They recommend getting second opinions from major academic centers to confirm the best treatment combination.
International patients can begin liver cancer treatment in Israel within 3 to 5 days of arrival. Evaluation starts immediately after online medical file review. If diagnostic scans are current, specialists can confirm a treatment plan within 48 to 72 hours of the first consultation.
Bookimed Expert Insight: Israeli oncology centers like Sheba Medical Center and Sourasky prioritize multidisciplinary tumor board reviews for stage 3 cases. This ensures that surgeons, hepatologists, and interventional radiologists evaluate resectability together. Choosing a center with specialized hepatobiliary units typically shortens the path from initial scan to the first procedure by at least 48 hours.
Patient Consensus: Patients note that arriving with complete pathology reports and recent PET-CT scans avoids redundant testing delays. They emphasize that while consultations happen quickly, the real key to speed is having a dedicated coordinator handle medical translations before landing.